.Nature Medication, Released online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) treatment of people with HER2+ sophisticated bosom cancer and also energetic or steady human brain metastases showed constant intracranial task as well as systemic efficiency of T-DXd.